UK start­up NodThera banks a $40M round with plans to con­quer a close­ly-stud­ied in­flam­ma­to­ry tar­get

A start­up in Cam­bridge, UK called NodThera has banked a $40 mil­lion A round to dig deep­er in­to de­vel­op­ing small mol­e­cules tar­get­ing NL­RP3, a rather no­to­ri­ous in­flam­ma­some that’s been linked to a va­ri­ety of in­flam­ma­to­ry con­di­tions.

CEO Alan Watt ex­plains that he was re­search­ing this tar­get a decade ago when he worked at Glax­o­SmithK­line in a se­nior re­search po­si­tion. “At that point,” he says, “we didn’t find any chem­i­cal leads.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA